DELCATH SYSTEMS, INC. Logo

DELCATH SYSTEMS, INC.

Interventional oncology company treating liver cancers with targeted chemotherapy.

DCTH | US

Overview

Corporate Details

ISIN(s):
US24661P8077
LEI:
Country:
United States of America
Address:
566 QUEENSBURY AVENUE, 12804 QUEENSBURY

Description

Delcath Systems, Inc. is a commercial-stage interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company develops and commercializes proprietary products for percutaneous hepatic perfusion (PHP), a minimally-invasive procedure designed to administer high-dose chemotherapy directly to the liver while controlling systemic exposure. Its flagship product in the United States is the HEPZATO KIT™ (melphalan/hepatic delivery system), an FDA-approved drug/device combination product for treating adult patients with metastatic uveal melanoma. In Europe, the company markets the CHEMOSAT® Hepatic Delivery System, a medical device for the same procedure.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2014-07-10 22:55
PRIMARY DOCUMENT
English 7.0 KB
2014-07-10 12:09
PRIMARY DOCUMENT
English 6.7 KB
2014-07-10 00:51
PRIMARY DOCUMENT
English 7.0 KB
2014-07-10 00:39
PRIMARY DOCUMENT
English 6.8 KB
2014-07-10 00:39
PRIMARY DOCUMENT
English 6.8 KB
2014-07-10 00:38
PRIMARY DOCUMENT
English 6.7 KB
2014-07-10 00:38
PRIMARY DOCUMENT
English 6.7 KB
2014-07-10 00:37
PRIMARY DOCUMENT
English 6.6 KB
2014-07-10 00:37
PRIMARY DOCUMENT
English 6.8 KB
2014-07-09 23:04
FORM 8-K
English 10.2 KB
2014-06-12 22:05
FORM 8-K
English 9.8 KB
2014-05-28 22:46
FORM 8-K
English 459.5 KB
2014-05-08 15:21
FORM 8-K
English 36.1 KB
2014-05-07 22:40
DELCATH SYSTEMS INC 10-Q 3-31-2014
English 965.1 KB
2014-04-30 18:20
DEF 14A
English 223.9 KB

Automate Your Workflow. Get a real-time feed of all DELCATH SYSTEMS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DELCATH SYSTEMS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DELCATH SYSTEMS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CORCEPT THERAPEUTICS INC Logo
Develops and commercializes cortisol-modulating medications for severe disorders.
United States of America
CORT
Corline Biomedical AB Logo
Develops heparin-based solutions for medical devices and regenerative medicine.
Sweden
CLBIO
CorMedix Inc. Logo
Biopharma firm developing therapeutics for infectious and inflammatory diseases.
United States of America
CRMD
Corvus Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing therapies for immune diseases and cancer.
United States of America
CRVS
Cosma Spolka Akcyjna Logo
Manufactures and distributes hemp and cannabis products for humans and animals.
Poland
COS
COSMO Pharmaceuticals N.V. Logo
A specialty pharmaceutical firm focused on gastroenterology, dermatology, and healthtech.
Netherlands
COPN
Cosmos Health Inc. Logo
Vertically integrated healthcare group in the nutraceutical and pharmaceutical sectors.
United States of America
COSM
Coya Therapeutics, Inc. Logo
Clinical-stage biotech developing therapies to enhance regulatory T cell function.
United States of America
COYA
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Logo
Clinical-stage biotech firm focused on regenerative medicine and immunotherapy.
United States of America
CELZ
CRESCENT BIOPHARMA, INC. Logo
Biopharmaceutical company researching and developing a pipeline of cancer therapies.
United States of America
CBIO

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.